Clinical efficacy and therapy response prediction of neoadjuvant dalpiciclib plus letrozole in postmenopausal patients with HR+/HER2- stage II-III breast cancer (DARLING 01): a single-arm, open-label, exploratory study
新辅助达匹西利联合来曲唑治疗HR+/HER2- II-III期绝经后乳腺癌患者的临床疗效和治疗反应预测(DARLING 01):一项单臂、开放标签、探索性研究
期刊:Breast Cancer Research
影响因子:5.6
doi:10.1186/s13058-025-01976-0
Zhang, Lina; Liu, Yueping; Yang, Chao; Ma, Jie; Li, Yuntao; Luo, Ruizhen; Han, Jianjun; Wang, Xiaochun; Zhang, Zhisheng; Ma, Li; Cai, Haifeng; Kong, Xiangshun; Wang, Zunyi; Zhou, Xinping; Shi, Jiajie; Zhang, Yanshou; Wang, Meiqi; Wang, Jiaxing; Geng, Cuizhi